AbbVie (ABBV) Return on Equity (2013 - 2026)

AbbVie has disclosed Return on Equity across 14 years of filings, most recently posting 0.01% for Q1 2026.

• In Q1 2026, Return on Equity fell 2.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 2.0% YoY), while the FY2025 annual figure was 0.9%, up 89.0% from the prior year.
• Return on Equity advanced to 0.01% in Q1 2026, from 0.01% in the prior quarter.
• Over the last five years, Return on Equity for ABBV reached as high as 0.06% in Q2 2025 and fell as low as 0.02% in Q3 2025.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.01%.
• The widest YoY moves for Return on Equity: up 5 bps in 2025, down 3 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then tumbled by 43 bps to 0.0% in 2023, then jumped by 126 bps to 0.01% in 2024, then slumped by 258 bps to 0.01% in 2025, then soared by 49 bps to 0.01% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.01%, 0.01%, and 0.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.